CSTA | Cystatin A (stefin A) | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CTAG1A | Cancer/testis antigen 1A | Cancer-related genes
| | | | | Tissue enriched |
CTSG | Cathepsin G | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
DCT | Dopachrome tautomerase | Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
DCUN1D1 | DCN1, defective in cullin neddylation 1, domain containing 1 | | | | | | Tissue enriched |
DNASE1 | Deoxyribonuclease I | Disease related genes Enzymes Potential drug targets Predicted secreted proteins
| | | | | Group enriched |
DUSP9 | Dual specificity phosphatase 9 | Enzymes
| | | | | Group enriched |
EBI3 | Epstein-Barr virus induced 3 | Predicted secreted proteins
| | | | | Tissue enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EHD2 | EH-domain containing 2 | | | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FABP4 | Fatty acid binding protein 4, adipocyte | Cancer-related genes Plasma proteins
| | | | | Tissue enriched |
FCER2 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Group enriched |
FCN1 | Ficolin (collagen/fibrinogen domain containing) 1 | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
FGB | Fibrinogen beta chain | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FHL2 | Four and a half LIM domains 2 | | | | | | Group enriched |
FLG | Filaggrin | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enriched |
FMR1NB | Fragile X mental retardation 1 neighbor | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
FOSL1 | FOS-like antigen 1 | Cancer-related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
GAP43 | Growth associated protein 43 | Plasma proteins Transporters
| | | | | Tissue enriched |
GLDC | Glycine dehydrogenase (decarboxylating) | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| | | | | Group enriched |
GPRC5A | G protein-coupled receptor, family C, group 5, member A | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HOXB13 | Homeobox B13 | Transcription factors
| | | | | Group enriched |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
IKZF3 | IKAROS family zinc finger 3 (Aiolos) | Transcription factors
| | | | | Tissue enhanced |
IRF8 | Interferon regulatory factor 8 | Disease related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
KHDRBS3 | KH domain containing, RNA binding, signal transduction associated 3 | | | | | | Group enriched |
KIF2C | Kinesin family member 2C | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
KLHL41 | Kelch-like family member 41 | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enriched |
KRT13 | Keratin 13 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enriched |
KRT17 | Keratin 17 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
KRT5 | Keratin 5 | Disease related genes Plasma proteins
| | | | | Group enriched |
KYNU | Kynureninase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LCK | Lymphocyte-specific protein tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
LPCAT2 | Lysophosphatidylcholine acyltransferase 2 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Predicted membrane proteins
| | | | | Tissue enhanced |
MAGEC1 | Melanoma antigen family C, 1 | Cancer-related genes Plasma proteins
| | | | | Tissue enriched |
MAP1B | Microtubule-associated protein 1B | Plasma proteins
| | | | | Tissue enhanced |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
MAP6 | Microtubule-associated protein 6 | | | | | | Tissue enhanced |
MARC1 | Mitochondrial amidoxime reducing component 1 | Mitochondrial proteins
| | | | | Tissue enhanced |
MB | Myoglobin | Candidate cardiovascular disease genes Plasma proteins
| | | | | Group enriched |
MBNL3 | Muscleblind-like splicing regulator 3 | | | | | | Tissue enhanced |
MEST | Mesoderm specific transcript | Predicted secreted proteins
| | | | | Tissue enriched |
MLANA | Melan-A | Predicted membrane proteins
| | | | | Tissue enriched |